Anacor Pharmaceuticals, Inc. Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2015 12 months to Dec 31, 2015	FY2014 12 months to Dec 31, 2014	FY2013 12 months to Dec 31, 2013	FY2012 12 months to Dec 31, 2012	FY2011 12 months to Dec 31, 2011
Operating activities
Net income (loss)
Adjustments to reconcile net income (loss) to net cash (used in) provided by operating activities:
Depreciation and amortization
Accretion and amortization of debt discount and debt issuance costs
Stock-based compensation
Amortization of premium on investments
Accrual of final payment on notes payable
Gain (loss) on early extinguishment of debt
Deferred income tax benefit
Changes in assets and liabilities:
Contract receivables
Government grant receivable
Inventory
Prepaid expenses and other current assets
Other assets
Accounts payable
Accrued liabilities
Income taxes payable
Other current liabilities
Deferred revenue
Deferred rent

Net cash (used in) provided by operating activities
Investing activities
Transfers from (to) restricted investments, net
Purchases of investments
Maturities of investments
Purchases of property and equipment
Net cash provided by (used in) investing activities
Financing activities
Proceeds from the sale of redeemable common stock, net of issuance costs
Proceeds from the sale of common stock, net of issuance costs
Proceeds from employee stock plan purchases and the exercise of stock options by employees and nonemployee advisors
Proceeds from the issuance of convertible senior notes
Proceeds from the issuance of notes payable
Principal payments on notes payable
Final payment on notes payable
Payment of financing fee, debt issuance costs and loan restructuring fee
Payment of financing fee, prepayment penalty and debt issuance costs
Net cash provided by financing activities
Proceeds from employee stock plan purchases and the exercise of stock options by employees and consultants

Net increase (decrease) in cash and cash equivalents
Cash and cash equivalents at beginning of year
Cash and cash equivalents at end of year
Supplemental disclosure of cash flow information
Cash paid for interest, including final payment on notes payable and payment of prepayment penalty
Supplemental schedule of noncash investing and financing activities
Purchases of property and equipment recorded in accounts payable
Conversion of convertible senior notes to common stock
Fair value of warrants to purchase common stock issued in connection with notes payable

Comments